The impact of pharmaceutical policy measures: An endogenous structural-break approach

Social Science and Medicine

Volumn 71, Issue 3, 2010, Pages 440-450

  Barros, Pedro Pita ^a   Nunes, Luis C ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

COMMODITY PRICE; CONSUMPTION BEHAVIOR; DRUG; GOVERNMENT; HEALTH EXPENDITURE; HEALTH POLICY; PRICE DETERMINATION; PRICE DYNAMICS; PUBLIC SPENDING;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG LEGISLATION; EMPIRICISM; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE COST; HEALTH SERVICE; HUMAN; PHARMACEUTICAL CARE; PORTUGAL;

DRUG COSTS; DRUG UTILIZATION; DRUGS, GENERIC; ECONOMIC COMPETITION; EMPIRICAL RESEARCH; EUROPE; FEES, PHARMACEUTICAL; GOVERNMENT REGULATION; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, STATISTICAL; NATIONAL HEALTH PROGRAMS; PHARMACEUTICAL PREPARATIONS; PORTUGAL;

PORTUGAL;

EID: 77954034118     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2010.04.020     Document Type: Article

References (12)

1. Andersson K., Petzold M., Sonesson C., Lonnroth K., Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time-series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 2006, 79(2):231-243.
2. Barros P.P., Simões J.A. Portugal: health system review. Health Systems in Transition 2007, 9(5):1-150.
3. Clemente J., Marcuello C., Montanes A. Pharmaceutical expenditure, total health-care expenditure and GDP. Health Economics 2008, 17(10):1187-1206.
4. Fiorio, C. & Siciliani, L. The demand for pharmaceuticals: evidence from Italy. Economic Modelling, forthcoming.
5. Harvey A.C. Forecasting, structural time series models and the Kalman filter 1989, Cambridge University Press, Cambridge.
6. Harvey A.C., Koopman S.J. Diagnostic checking of unobserved-components time series models. Journal of Business & Economic Statistics, American Statistical Association 1992, 10(4):377-389.
7. Koopman S.J., Harvey A.C., Doornik J.A., Shephard N. STAMP 8: Structural time series analyser, modeller and predictor 2007, Timberlake Consultants Press.
8. Lee Y.-C., Yan M.-C., Huang Y.-T., Liu C.-H., Chen S.-B. Impacts of cost-containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics 2006, 24(9):891-902.
9. Mossialos E., Brogan D., Walley T. Pharmaceutical pricing in Europe: weighing up the options. International Social Security Review 2006, 59(3):3-25.
10. Okunade A., Suraratdecha C. The pervasiveness of pharmaceutical expenditure inertia in the OECD countries. Social Science & Medicine 2006, 63(1):225-236.
11. Ong M., Catalano R., Hartig T. A time-series analysis of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clinical Therapeutics 2003, 25(4):1262-1275.
12. Sisto A., Zanola R. The determinants of public pharmaceutical expenditures: does Italian health federalism impact on them? Available at SSRN. http://ssrn.com/abstract%3D869762.